Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bladder Cancer
  Free Subscription

Articles published in
J Urol
    November 2026
  1. DECASTRO GJ, Joffe BI, Stein MN, Abate-Shen C, et al
    A Phase 2 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Nonmuscle-Invasive Bacillus Calmette-Guerin-Unresponsive Urothelial Carcinoma of the Bladder.
    J Urol. 2026;216:676-684.
    >> Share

  2. CHANG SS, Chamie K, Seabury CA, Gonzalgo ML, et al
    Durable Responses and Cystectomy Avoidance With Interleukin-15 Receptor Agonist NAI Plus Bacillus Calmette-Guerin in Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer With Carcinoma In Situ +/- Papillary Disease.
    J Urol. 2026;216:663-675.
    >> Share

    October 2026
  3. STROUD M, Talwar R, Bjurlin MA
    The Missing Comparator: Smoking Cessation Cost-Effectiveness in the Era of Novel Bladder Cancer Therapies.
    J Urol. 2026 Oct 28:101097JU0000000000005359. doi: 10.1097/JU.0000000000005359.
    >> Share

  4. JAYRAM G, Shore ND, Tyson M, Pieczonka C, et al
    PD09-07 Durvalumab in Combination with Bacillus Calmette-Guerin for Bacillus Calmette-Guerin-Naive, High-Risk Non-Muscle-Invasive Bladder Cancer: Primary Results from a US-Based, Phase IIIB, Open-Label, Single-Arm, Multicenter Study (PATAPSCO): Erratu
    J Urol. 2026;216:606.
    >> Share

  5. SHORE ND, Nishiyama H, Redorta JP, Krawczynski M, et al
    Durvalumab in Combination with Bacillus Calmette-Guerin Induction and Maintenance Therapy for Bacillus Calmette-Guerin-Naive, High-Risk Non-muscle-Invasive Bladder Cancer: Expanded Efficacy and Safety Analyses from POTOMAC: Erratum.
    J Urol. 2026;216:607.
    >> Share

  6. GARMAN TS, Lokeshwar S, Campbell J, Su ZT, et al
    Phase 2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guerin?Naive Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3-Year Outcomes.
    J Urol. 2026;216:540-550.
    >> Share

  7. GAFFNEY CD, Alam SM, Wald G, Sjoberg D, et al
    A Phase I Clinical Trial of Chemoimmunotherapy with Alternating Intravesical Gemcitabine and Bacillus Calmette-Guerin (GemBCG) for BCG-Exposed High-Grade Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2026 Oct 1:101097JU0000000000005324. doi: 10.1097/JU.0000000000005324.
    >> Share

    September 2026
  8. NUSBAUM DJ, Gilbert SM, Li R
    Simpler risk stratification and new options for recurrent low-grade disease: 2026 update to the AUA/SUO non-muscle invasive bladder cancer guideline.
    J Urol. 2026 Sep 24:101097JU0000000000005323. doi: 10.1097/JU.0000000000005323.
    >> Share

  9. MATULEWICZ RS, Gold SA, Nicholson A, Candelieri-Surette D, et al
    Bladder Cancer Incidence in Patients with Microhematuria at the Veterans Health Administration.
    J Urol. 2026 Sep 16:101097JU0000000000005312. doi: 10.1097/JU.0000000000005312.
    >> Share

  10. CLARK PE, Holzbeierlein J, Chang SS, Djaladat H, et al
    2026 Updates to the Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline.
    J Urol. 2026 Sep 4:101097JU0000000000005280. doi: 10.1097/JU.0000000000005280.
    >> Share

    August 2026
  11. JOFFE BI, Pingle SR, Laplaca C, Christin JR, et al
    Non-Muscle Invasive Recurrence and Management During Surveillance in Patients with Muscle-Invasive Bladder Cancer Who Achieve Clinical Complete Response to Neoadjuvant Chemotherapy.
    J Urol. 2026 Aug 26:101097JU0000000000005278. doi: 10.1097/JU.0000000000005278.
    >> Share

  12. GABRIEL PE, Zhu A, Xylinas E, Sfakianos JP, et al
    Beyond the NMIBC-MIBC Dichotomy: Integrating Molecular Biomarkers into Bladder Cancer Risk Stratification.
    J Urol. 2026 Aug 11:101097JU0000000000005255. doi: 10.1097/JU.0000000000005255.
    >> Share

    June 2026
  13. JOYCE DD, Sharma V, Boorjian SA
    With great cost comes great responsibility: who will own the rising costs of bladder cancer care?
    J Urol. 2026 Jun 26:101097JU0000000000005185. doi: 10.1097/JU.0000000000005185.
    >> Share

  14. ST-LAURENT MP, Din S, Moryousef J, Lajkosz K, et al
    Oncological Outcomes of Non-Muscle Invasive Bladder Cancer in Patients Aged
    J Urol. 2026 Jun 24:101097JU0000000000005183. doi: 10.1097/JU.0000000000005183.
    >> Share

  15. PRASAD S
    Reply: UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A 24-Month Duration of Response Results from the Phase 3 ENVISION Trial.
    J Urol. 2026 Jun 2:101097JU0000000000005128. doi: 10.1097/JU.0000000000005128.
    >> Share

    May 2026
  16. BAHLBURG H, Maas M, Contreras-Sanz A, Othman D, et al
    Urine tumor DNA testing identifies recurrence and monitors therapy response in patients with high-risk non-muscle-invasive bladder cancer receiving intravesical bacillus Calmette-Guerin.
    J Urol. 2026 May 20:101097JU0000000000005130. doi: 10.1097/JU.0000000000005130.
    >> Share

  17. JOYCE DD, Sharma V, Ratcliff GE, Barocas DA, et al
    Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy plus BCG for High-Risk Non-muscle Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.
    J Urol. 2026 May 18:101097JU0000000000005126. doi: 10.1097/JU.0000000000005126.
    >> Share

  18. PEDERSEN GL, Mogensen K, Rosthoj S, Erikson MS, et al
    In-Office Laser Coagulation of Ta Bladder Tumor Compared With Transurethral Resection of Bladder Tumor: 12 Months Follow-Up Randomized Clinical Trial.
    J Urol. 2026;215:535-543.
    >> Share

  19. GHOREIFI A, Lotan Y
    Letter: Preoperative ctDNA Predicts Upstaging and Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy.
    J Urol. 2026 May 1:101097JU0000000000005078. doi: 10.1097/JU.0000000000005078.
    >> Share

    April 2026
  20. LI EV, Sharma V, Boorjian SA
    Are ctDNA and utDNA the new PSA for Clinically Localized Muscle Invasive Bladder Cancer in the Enfortumab Vedotin/Pembrolizumab Era?
    J Urol. 2026 Apr 29:101097JU0000000000005074. doi: 10.1097/JU.0000000000005074.
    >> Share

  21. UDEDIBIA E, Solosky K, Macdonald EJ, Gaines J, et al
    Critical Analysis of the AUA 2020/2025 Microscopic Hematuria Guidelines to Predict Urothelial but Not Renal Cortical Neoplasms and Validation of the Individual Clinical Components in Risk Stratification for Urothelial Neoplasms but Not Renal Cortical
    J Urol. 2026;215:441-449.
    >> Share

    March 2026
  22. PRASAD SM, Shishkov D, Mihaylov NV, Genov P, et al
    UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial.
    J Urol. 2026 Mar 25:101097JU0000000000005041. doi: 10.1097/JU.0000000000005041.
    >> Share

  23. BEN-DAVID R, Raizenne BL, Eraky A, Duquesne I, et al
    Preoperative ctDNA Predicts Upstaging and Recurrence in High-Risk Non-Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy.
    J Urol. 2026 Mar 17:101097JU0000000000005034. doi: 10.1097/JU.0000000000005034.
    >> Share

  24. ANDERSON CB, Sfakianos JP
    Circulating Tumor DNA in Bladder Cancer: A New Treatment Paradigm?
    J Urol. 2026;215:256-257.
    >> Share

  25. ZHAO D, Khatri VM, Nakashima JY, Chadha J, et al
    Early Detection of Metastatic Progression by Circulating Tumor DNA in Patients Undergoing Bladder-Preserving Trimodality Therapy.
    J Urol. 2026;215:305-315.
    >> Share

  26. ELIAS R, Aragaki AK, Hoffman-Censits JH, Hahn NM, et al
    Intratumoral Expression of a Composite B Cell / CD8 T Cell Biomarker Stratifies Overall Survival by Circulating Tumor DNA Status and Benefit From Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Carcinoma.
    J Urol. 2026;215:294-304.
    >> Share

    February 2026
  27. RITCH C, Anderson CB
    Cystoscopic Fulguration for Patients with Recurrent Low-Grade Bladder Cancer.
    J Urol. 2026 Feb 18:101097JU0000000000004974. doi: 10.1097/JU.0000000000004974.
    >> Share

  28. ZHANG S, Li T, Li D, Yin Y, et al
    Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined with Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial.
    J Urol. 2026 Feb 17:101097JU0000000000004993. doi: 10.1097/JU.0000000000004993.
    >> Share

  29. LAZAROVICH A, Nusbaum DJ, Agarwal PK, Modi PK, et al
    Clinical Trial Design for Bacillus Calmette-Guerin-Unresponsive Non-Muscle Invasive Bladder Cancer-Single-Arm Design Was Necessary, Randomized Trials Are Now Essential.
    J Urol. 2026 Feb 11:101097JU0000000000004960. doi: 10.1097/JU.0000000000004960.
    >> Share

  30. REZAEE ME, Higgins MI, Su ZT, Sepehri S, et al
    Results from the ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) Randomized Controlled Trial.
    J Urol. 2026 Feb 9:101097JU0000000000004983. doi: 10.1097/JU.0000000000004983.
    >> Share

    January 2026
  31. CHANG SS, Chamie K, Kramolowsky E, Gonzalgo ML, et al
    Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guerin in Bacillus Calmette-Guerin-Unresponsive Papillary-Only Nonmuscle-Invasive Bladder
    J Urol. 2026;215:44-56.
    >> Share

    December 2025
  32. STOVER AM, Mueller D, Carda-Auten J, Hilton A, et al
    Perceived Impact on Patient Routines/Responsibilities for Surgery and a Nonsurgical Primary Treatment Option in Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: Findings From the ENVISION Phase 3 Trial: Erratum.
    J Urol. 2025;214:674.
    >> Share

  33. DONAT SM, Tin AL, Vickers AJ, Herr H, et al
    Neoadjuvant Chemotherapy With Transurethral Resection for Bladder Preservation: 15-Year Follow-Up of the Retained Bladder.
    J Urol. 2025;214:591-600.
    >> Share

    November 2025
  34. GONZALEZ-PADILLA DA, Subiela JD, Villacampa-Auba F
    Immune checkpoint inhibitors for high-risk non-muscle invasive bladder cancer: Lessons learnt from the CREST and POTOMAC trials.
    J Urol. 2025 Nov 25:101097JU0000000000004864. doi: 10.1097/JU.0000000000004864.
    >> Share

  35. WALD G, Lang J, Alkazemi H, Zhang A, et al
    Combination Strategies to Enhance Bacillus Calmette-Guerin Efficacy for Non-Muscle Invasive Bladder Cancer.
    J Urol. 2025 Nov 21:101097JU0000000000004848. doi: 10.1097/JU.0000000000004848.
    >> Share

  36. FENG Y, Zhou S, Huang S, Yu Z, et al
    Letter: Prolonged Progression-Free Survival, Disease-Free Survival and Cystectomy Avoidance With IL-15 Receptor Lymphocyte-Stimulating Agent NAI Plus Bacillus Calmette-Guerin in Bacillus Calmette-Guerin-Unresponsive Papillary-Only Nonmuscle-Invasive B
    J Urol. 2025 Nov 13:101097JU0000000000004792. doi: 10.1097/JU.0000000000004792.
    >> Share

  37. MEEKS JJ, van der Heijden MS, Powles T, Galsky MD, et al
    PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: Erratum.
    J Urol. 2025;214:556.
    >> Share

  38. DONAHUE TF, Assel M, Cha EK, Goh A, et al
    Evaluating Benefits of Peristomal Mesh Placement at the Time of Radical Cystectomy and Ileal Conduit Formation: A Phase 3, Randomized Controlled Trial.
    J Urol. 2025;214:487-495.
    >> Share

    October 2025
  39. CHUNG D, Kassouf W, Agnihotram R, Alday H, et al
    Outcomes Among Rural and Urban Patients with High-risk NMIBC: Results from the Canadian Bladder Cancer Information System (CBCIS).
    J Urol. 2025 Oct 30:101097JU0000000000004836. doi: 10.1097/JU.0000000000004836.
    >> Share

  40. GUTIERREZ J, Ayub A, Piva SE, Shirk JD, et al
    IP11-07 A 3D Tumor Map for the Surgical Management of Bladder Cancer: Feasibility and Preliminary Analysis: Erratum.
    J Urol. 2025;214:458.
    >> Share

    June 2025
  41. MOYER JA, Durant AM, Nguyen MV, Mi L, et al
    Use of Rectal Diazepam to Prevent Bladder Spasms and Leakage of Medication During Intravesical Administration of Nadofaragene Firadenovec for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2025 Jun 26:101097JU0000000000004658. doi: 10.1097/JU.0000000000004658.
    >> Share

  42. KOTI M, Michaud E, Siemens DR
    Non-modifiable drivers of BCG response: Considerations of age, sex and chronic inflammation for the management of non-muscle invasive bladder cancer.
    J Urol. 2025 Jun 10:101097JU0000000000004632. doi: 10.1097/JU.0000000000004632.
    >> Share

  43. VENKATRAMANI V, Reis IM, Gonzalgo ML, Swain S, et al
    Comparison of Complication and Readmission Rates Between Robot-Assisted and Open Radical Cystectomy: Results From the Randomized RAZOR Clinical Trial.
    J Urol. 2025;213:684-692.
    >> Share

    April 2025
  44. HUSSEIN AA, Mahmood AW, Ahmad A, Houenstein H, et al
    Do Prophylactic Antibiotics Decrease the Rate of Urinary Tract Infections after Robot-Assisted Radical Cystectomy? A Randomized Controlled Trial.
    J Urol. 2025 Apr 25:101097JU0000000000004586. doi: 10.1097/JU.0000000000004586.
    >> Share

  45. LOTAN Y, Li R, Chang SS
    AI Biomarkers Predict Poor Efficacy of BCG Rechallenge in Previously BCG-Treated Non-muscle Invasive Bladder Cancer.
    J Urol. 2025 Apr 16:101097JU0000000000004541. doi: 10.1097/JU.0000000000004541.
    >> Share

  46. ZHONG Y, Wei J, Jiang R
    Letter: Hybrid 3-Tier Bladder Cancer Grade: The Mutually Beneficial Marriage of 2 Grading Systems.
    J Urol. 2025 Apr 15:101097JU0000000000004555. doi: 10.1097/JU.0000000000004555.
    >> Share

  47. TALLMAN JE, Vertosick EA, Alam SM, Baky FJ, et al
    Perioperative Complications and Omission of Ureteral Stents During Robot-Assisted Radical Cystectomy With Intracorporeal Ileal Conduit.
    J Urol. 2025;213:437-446.
    >> Share

  48. AHMED ME, Andrews JR, Mahmoud AM, Reitano G, et al
    Intraoperative Tranexamic Acid in Radical Cystectomy: Impact on Bleeding, Thromboembolism, and Survival Outcomes.
    J Urol. 2025;213:447-454.
    >> Share

    March 2025
  49. KAMAT AM, van Rhijn BWG, Van der Kwast T
    Hybrid 3-Tier Bladder Cancer Grade: The Mutually Beneficial Marriage Of Two Grading Systems.
    J Urol. 2025 Mar 25:101097JU0000000000004542. doi: 10.1097/JU.0000000000004542.
    >> Share

  50. STOVER AM, Mueller D, Carda-Auten J, Hilton A, et al
    Perceived Impact on Patient Routines/Responsibilities for Surgery and a Nonsurgical Primary Treatment Option in Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: Findings From the ENVISION Phase 3 Trial.
    J Urol. 2025 Mar 6:101097JU0000000000004511. doi: 10.1097/JU.0000000000004511.
    >> Share

    February 2025
  51. KHENE ZE, Bhanvadia R, Attia S, Ito W, et al
    Gemcitabine versus Bacillus Calmette-Guerin for Intravesical Therapy in Treatment-Naive Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer.
    J Urol. 2025 Feb 10:101097JU0000000000004472. doi: 10.1097/JU.0000000000004472.
    >> Share

  52. HOLZBEIERLEIN JM
    Reply: Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.
    J Urol. 2025 Feb 10:101097JU0000000000004452. doi: 10.1097/JU.0000000000004452.
    >> Share

  53. HEER R, Boaz RJ, Tan WS, Gravestock P, et al
    Letter: Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.
    J Urol. 2025 Feb 7:101097JU0000000000004431. doi: 10.1097/JU.0000000000004431.
    >> Share

  54. SHARMA V, Fadel A, Tollefson MK, Psutka SP, et al
    Artificial Intelligence-Based Assessment of Preoperative Body Composition Is Associated With Early Complications After Radical Cystectomy.
    J Urol. 2025;213:228-237.
    >> Share

    December 2024

  55. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment: Erratum.
    J Urol. 2024;212:936.
    >> Share

    November 2024
  56. RAMOS P, Bras JP, Dias C, Bessa-Goncalves M, et al
    Uromonitor(R): Clinical Validation and Performance Assessment of a Urinary Biomarker within the Surveillance of Non-Muscle Invasive Bladder Cancer Patients.
    J Urol. 2024 Nov 19:101097JU0000000000004335. doi: 10.1097/JU.0000000000004335.
    >> Share

  57. PIETZAK E, Anderson CB
    What is the Standard of Care For Multifocal Low-Grade Bladder Cancer?
    J Urol. 2024 Nov 18:101097JU0000000000004316. doi: 10.1097/JU.0000000000004316.
    >> Share

    October 2024
  58. VILLEGAS E, Lajkosz K, Din S, Kuk C, et al
    Long-term recurrence risk, metastatic potential and length of cystoscopic surveillance of low-grade non-muscle invasive bladder cancer.
    J Urol. 2024 Oct 29:101097JU0000000000004305. doi: 10.1097/JU.0000000000004305.
    >> Share

  59. PRASAD SM, Shishkov D, Mihaylov NV, Khuskivadze A, et al
    Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION).
    J Urol. 2024 Oct 24:101097JU0000000000004296. doi: 10.1097/JU.0000000000004296.
    >> Share

  60. LOTAN Y, Krishna V, Abuzeid WM, Launer B, et al
    Predicting response to intravesical BCG in high-risk non-muscle invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12 center cohort.
    J Urol. 2024 Oct 9:101097JU0000000000004278. doi: 10.1097/JU.0000000000004278.
    >> Share

  61. CHRISTOPH SOERENSEN SJ, Schmidt B, Thomas IC, Montez-Rath ME, et al
    An Automated Electronic Health Record Score to Estimate Length of Stay and Readmission in Patients Undergoing Radical Cystectomy for Bladder Cancer.
    J Urol. 2024 Oct 2:101097JU0000000000004262. doi: 10.1097/JU.0000000000004262.
    >> Share


  62. Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guerin Therapy? Erratum.
    J Urol. 2024;212:641.
    >> Share

  63. PASSARELLI R, Ghodoussipour S, Packiam VT
    Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
    J Urol. 2024;212:622-623.
    >> Share

    September 2024
  64. PETERSEN E, Holt S, Browning A, Cavanaugh D, et al
    Characterizing Psychological Resources and Resilience in Patients With Bladder Cancer: Associations With Frailty and Quality of Life.
    J Urol. 2024 Sep 30:101097JU0000000000004257. doi: 10.1097/JU.0000000000004257.
    >> Share

  65. WU Y, Zhang Z
    Letter: The Influence of Dietary Isothiocyanates on the Effectiveness of Mitomycin C and Bacillus Calmette-Guerin in Treating Nonmuscle-Invasive Bladder Cancer.
    J Urol. 2024 Sep 27:101097JU0000000000004248. doi: 10.1097/JU.0000000000004248.
    >> Share

  66. GHOREIFI A, Daneshmand S
    Technical Considerations to Minimize False-Positive Findings in Blue Light Cystoscopy for Non-muscle-invasive Bladder Cancer.
    J Urol. 2024 Sep 16:101097JU0000000000004250. doi: 10.1097/JU.0000000000004250.
    >> Share

  67. ANDERSON CB
    What Is the Future of Cystoscopy for Detecting Urothelial Carcinoma?
    J Urol. 2024;212:399-400.
    >> Share

    July 2024
  68. HALSTUCH D, Kool R, Marcq G, Breau RH, et al
    The Impact of Histologic Subtypes on Clinical Outcomes After Radiation-Based Therapy for Muscle-Invasive Bladder Cancer.
    J Urol. 2024 Jul 25:101097JU0000000000004160. doi: 10.1097/JU.0000000000004160.
    >> Share

  69. CHANG SS
    Urological Oncology: Bladder, Penis, and Urethra Cancer, and Basic Principles of Oncology.
    J Urol. 2024 Jul 25:101097JU0000000000004120. doi: 10.1097/JU.0000000000004120.
    >> Share

  70. DINNEY CPN, Narayan VM
    Reply: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
    J Urol. 2024 Jul 5:101097JU0000000000004128. doi: 10.1097/JU.0000000000004128.
    >> Share

  71. LAZAROVICH A, Dahmen AS, Modi PK, Agarawal PK, et al
    Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology.
    J Urol. 2024;212:236-237.
    >> Share

  72. LOTAN Y, Daneshmand S, Shore N, Black P, et al
    A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria: The Safe Testing of Risk for Asymptomatic Microhematuria Trial.
    J Urol. 2024;212:41-51.
    >> Share

  73. PATEL SH, Gabrielson AT, Chan S, Schwartz D, et al
    A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guerin?Naive Nonmuscle-Invasive Urothelial Carcinoma of the Bladder.
    J Urol. 2024;212:95-103.
    >> Share

    June 2024
  74. LINSCOTT J, Li R
    Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
    J Urol. 2024 Jun 24:101097JU0000000000004122. doi: 10.1097/JU.0000000000004122.
    >> Share

  75. MEEKS JJ
    Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
    J Urol. 2024 Jun 19:101097JU0000000000004097. doi: 10.1097/JU.0000000000004097.
    >> Share

  76. CHANG SS
    Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology.
    J Urol. 2024 Jun 17:101097JU0000000000004092. doi: 10.1097/JU.0000000000004092.
    >> Share

  77. KASEB H, Leslie SW, Soon-Sutton TL, Aeddula NR, et al
    The Influence of Dietary Isothiocyanates on the Effectiveness of Mitomycin C and Bacillus Calmette-Guerin in Treating Nonmuscle-Invasive Bladder Cancer.
    J Urol. 2024 Jun 7:101097JU0000000000004070. doi: 10.1097/JU.0000000000004070.
    >> Share

  78. DJALADAT H, Ghoreifi A, Tejura T, Miranda G, et al
    Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): A Randomized Clinical Trial.
    J Urol. 2024;211:743-753.
    >> Share

    May 2024
  79. CHANG SS
    Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology.
    J Urol. 2024 May 17:101097JU0000000000004018. doi: 10.1097/JU.0000000000004018.
    >> Share

  80. NARAYAN VM, Boorjian SA, Alemozaffar M, Konety BR, et al
    Efficacy of Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non-muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial.
    J Urol. 2024 May 5:101097JU0000000000004020. doi: 10.1097/JU.0000000000004020.
    >> Share

  81. KARABURUN MC, Kuz ED, Akpinar C, Obaid K, et al
    Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guerin Therapy?
    J Urol. 2024 May 1:101097JU0000000000003990. doi: 10.1097/JU.0000000000003990.
    >> Share

    April 2024
  82. HOLZBEIERLEIN J, Bixler BR, Buckley DI, Chang SS, et al
    Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO GUIDELINE (2017; Amended 2020, 2024).
    J Urol. 2024 Apr 25:101097JU0000000000003981. doi: 10.1097/JU.0000000000003981.
    >> Share

  83. CHANG SS
    Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology.
    J Urol. 2024 Apr 22:101097JU0000000000003900. doi: 10.1097/JU.0000000000003900.
    >> Share

  84. KAY H, Silver SN, Smith AB, Basak R, et al
    Bladder Cancer Survivors Who Do Not Smoke Have Better Longitudinal Health Related Quality of Life Measures: An Assessment of the Comparative Effectiveness of Survivorship Health in Bladder Cancer (CEASE-BC) Study.
    J Urol. 2024 Apr 11:101097JU0000000000003964. doi: 10.1097/JU.0000000000003964.
    >> Share

  85. ALLORY Y, Culine S, Krucker C, Fontugne J, et al
    Impact of Divergent Differentiation and/or Histological Subtype of Urothelial Carcinoma on Patient Outcomes in the GETUG-AFU V05 VESPER Trial.
    J Urol. 2024;211:564-574.
    >> Share

    March 2024
  86. MONTORSI F, Moschini M, Gandaglia G, Briganti A, et al
    Letter: Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 +/- Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATL
    J Urol. 2024;211:482-483.
    >> Share

  87. GILL IS, Desai MM, Cacciamani GE, Khandekar A, et al
    Robotic Radical Cystectomy for Bladder Cancer: The Way Forward.
    J Urol. 2024;211:476-480.
    >> Share

  88. BOCHNER BH, Kamat AM, Bivalacqua TJ
    Open vs Robotic Cystectomy: Case Closed?
    J Urol. 2024;211:473-475.
    >> Share

    February 2024
  89. WEISS K, Abimbola O, Mueller D, Basak R, et al
    Feasibility, Acceptability, and Outcomes of a Mobile Health Tool for Radical Cystectomy Recovery.
    J Urol. 2024;211:266-275.
    >> Share

  90. KAY H, Matulewicz RS, Bjurlin MA
    Clearing the Smoke: Underreporting of Smoking Status in Food and Drug Administration-Approved Bladder Cancer Therapeutic Trials.
    J Urol. 2024 Feb 1:101097JU0000000000003853. doi: 10.1097/JU.0000000000003853.
    >> Share

    January 2024
  91. HOLZBEIERLEIN JM, Bixler BR, Buckley DI, Chang SS, et al
    Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.
    J Urol. 2024 Jan 24:101097JU0000000000003846. doi: 10.1097/JU.0000000000003846.
    >> Share

    November 2023
  92. SOOD A, Rudzinski JK, Labbate CV, Hensley PJ, et al
    Long-Term Oncological Outcomes in Patients Diagnosed with Non-Metastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience.
    J Urol. 2023 Nov 3:101097JU0000000000003778. doi: 10.1097/JU.0000000000003778.
    >> Share

    September 2023
  93. PRASAD SM
    Primary Chemoablation for Intermediate-Risk Low-Grade Bladder Cancer: New Paradigm or Added Uncertainty? Letter.
    J Urol. 2023 Sep 28:101097JU0000000000003729. doi: 10.1097/JU.0000000000003729.
    >> Share

  94. MURTHY PB, Sexton WJ
    Primary Chemoablation for Intermediate-risk Low-grade Bladder Cancer: New Paradigm or Added Uncertainty?
    J Urol. 2023 Sep 27:101097JU0000000000003702. doi: 10.1097/JU.0000000000003702.
    >> Share

  95. BREE KK, Navai N
    Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 Sep 25:101097JU0000000000003704. doi: 10.1097/JU.0000000000003704.
    >> Share

  96. BREE K, Navai N
    Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 Sep 25:101097JU0000000000003705. doi: 10.1097/JU.0000000000003705.
    >> Share

  97. CLEMENTS MB, Beech BB, Atkinson TM, Dalbagni GM, et al
    Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial. Reply.
    J Urol. 2023;210:408.
    >> Share

  98. WONG N, So WZ, Tiong HY
    Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial. Letter.
    J Urol. 2023;210:407-408.
    >> Share

    August 2023
  99. PRASAD SM, Huang WC, Shore ND, Hu B, et al
    Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 +/- Transurethral Resection of Bladder Tumor (TURBT) Compared to TURBT Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
    J Urol. 2023 Aug 7:101097JU0000000000003645. doi: 10.1097/JU.0000000000003645.
    >> Share

  100. TAN WS, Contieri R, Buffi NM, Lughezzani G, et al
    International Bladder Cancer Group Intermediate-risk Non-muscle Invasive Bladder Cancer (IBCG IR-NMIBC) Scoring System Predicts Outcomes of Patients on Active Surveillance.
    J Urol. 2023 Aug 3:101097JU0000000000003639. doi: 10.1097/JU.0000000000003639.
    >> Share

    July 2023
  101. JI J, Lai CH, Wang Q, Hu H, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic But Not Therapeutic. Letter.
    J Urol. 2023 Jul 6:101097JU0000000000003613. doi: 10.1097/JU.0000000000003613.
    >> Share


  102. PD44-11 Neoadjuvant Chemotherapy Increases Urinary and Bowel Anastomotic Failure in PT2-T4 Bladder Cancer Undergoing Radical Cystectomy.
    J Urol. 2023;210:222.
    >> Share

    June 2023
  103. COLEMAN JA, Clark PE, Bixler BR, Buckley DI, et al
    Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline.
    J Urol. 2023;209:1071-1081.
    >> Share

  104. WANG HH, Zhang TR, Ramakrishnan VM, Valovska MT, et al
    Long-term Urological Outcomes in Pelvic Genitourinary Rhabdomyosarcoma: A 48-Year Single-center Experience.
    J Urol. 2023;209:1202-1209.
    >> Share

    May 2023
  105. BREE KK, Kokorovic A, Westerman ME, Hensley PJ, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 May 22:101097JU0000000000003553. doi: 10.1097/JU.0000000000003553.
    >> Share

  106. TYSON MD, Morris D, Palou J, Rodriguez O, et al
    Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study.
    J Urol. 2023;209:890-900.
    >> Share

  107. GILBERT SM
    Will Patient-reported Outcomes Be the Key to Demonstrating the Value of Robotic Cystectomy? Data Are Accumulating but Clarity Is Not.
    J Urol. 2023;209:833-835.
    >> Share

  108. GHOREIFI A, Ladi-Seyedian SS, Piatti P, Chew YC, et al
    A Urine-based DNA Methylation Marker Test to Detect Upper Tract Urothelial Carcinoma: A Prospective Cohort Study.
    J Urol. 2023;209:854-862.
    >> Share

  109. KIRK PS, Lotan Y, Zargar H, Fairey AS, et al
    Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort.
    J Urol. 2023;209:882-889.
    >> Share

  110. YIP W, Sjoberg DD, Nogueira LM, Tracey AT, et al
    Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma.
    J Urol. 2023;209:863-871.
    >> Share

  111. CLEMENTS MB, Beech BB, Atkinson TM, Dalbagni GM, et al
    Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial.
    J Urol. 2023;209:901-910.
    >> Share

  112. LABBATE C, Woldu S, Murray K, Rose K, et al
    Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
    J Urol. 2023;209:872-881.
    >> Share

    April 2023
  113. MOSCHINI M, Necchi A, Briganti A, Montorsi F, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Letter.
    J Urol. 2023 Apr 10:101097JU0000000000003455. doi: 10.1097/JU.0000000000003455.
    >> Share

  114. PENG CK, Sung WW
    Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. Letter.
    J Urol. 2023;209:676-677.
    >> Share

  115. LOTAN Y, Raman JD, Konety B, Daneshmand S, et al
    Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.
    J Urol. 2023;209:762-772.
    >> Share

    March 2023
  116. STEINBERG RL, O'Donnell MA, Packiam VT
    Non-risk Adapted Sequential Intravesical Gemcitabine and Docetaxel for Non-muscle Invasive Bladder Cancer: The Time is Now.
    J Urol. 2023 Mar 31:101097JU0000000000003438. doi: 10.1097/JU.0000000000003438.
    >> Share

  117. PENG CK, Sung WW, Chen SL
    Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
    J Urol. 2023 Mar 9:101097JU0000000000003407. doi: 10.1097/JU.0000000000003407.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016